Tag: GlobeNewswire

Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA)

Vancouver, Canada, Oct. 08, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the publication of a patent application in Japan covering novel compositions and methods for treating dyskinesia, a neurological movement disorder characterized by involuntary movements. The published patent application covers the use of 3-Methylmethcathinone (“3-MMC”) for preventing, treating, or reducing dyskinesia symptoms, including pharmaceutical compositions comprising 3-MMC. The application also includes claims for combinations of 3-MMC with N-acylethanolamines, notably Palmitoylethanolamide (“PEA”, a compound with established anti‑inflammatory and neuroprotective properties.

These patent applications are part of the ongoing collaboration between Clearmind and NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage biotech company. Through this partnership with NeuroThera, PEA technology is integrated into Clearmind’s psychedelic-derived therapeutic programs. “

Our strategy is to build robust intellectual property protection around our novel therapeutic platforms and their broad potential across neurological disorders,” said Adi Zuloff-Shani, Ph.D., Chief Executive Officer of Clearmind. “The publication of the patent application in Japan and strengthens our global IP position for our 3-MMC-based approach to dyskinesia, including its combination with PEA.”

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its strategy is to build robust intellectual property protection around its novel therapeutic platforms and their broad potential across neurological disorders and strengthening our global IP position. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

VANCOUVER, British Columbia, Oct. 08, 2026 (GLOBE NEWSWIRE) — Trekor Metals Limited (TSX: TKO; NYSE American: TGB; LSE: TKO) (“Trekor” or the “Company”) is pleased to announce third quarter total production of 41 million pounds of copper from its 100%-owned Gibraltar mine and Florence Copper production facility.

Gibraltar produced 34 million pounds of copper and 380 thousand pounds of molybdenum in the quarter. The Connector Pit continued to deliver strong grades which, in addition to an increase in mill throughput and improved SX/EW plant performance, drove a 12% increase in quarterly production. Copper sales from Gibraltar totalled 31 million pounds in the period.

The Florence Copper ramp-up continued in the third quarter with steady monthly production growth. Total copper cathode production was seven million pounds, a 36% increase over the prior period. Sales for the quarter were seven million pounds.

Stuart McDonald, President & CEO of Trekor, commented, “Solid progress on the Florence Copper ramp- up continued in the third quarter with no wellfield performance issues of any significance. Initial flow rates across the wellfield continue to exceed expectations, and work is ongoing to optimize the balance between wellfield flows and PLS grade. The SX/EW plant has been operating very well, producing high-quality copper cathode with no impurities, and operated for several days last week at design capacity without issue. The one area where progress remains behind our initial plan is the wellfield expansion. Drilling rates have improved in recent months, but we are still about three months behind our original plan. We are now expecting 25 to 28 million pounds of copper production in 2026. Wells recently brought online, together with those expected to come online shortly, are anticipated to support a significant increase in cathode production, completing the ramp-up to full production capacity in early 2027.”

“Our Gibraltar mine had another strong quarter of operating performance, as higher grade ore was mined from the bottom of the Connector Pit. The transition back into more complex ore began later in the third quarter which impacted recoveries as expected. In the fourth quarter we expect lower grades and recoveries as mining transitions back to the upper benches of the Connector Pit. Based on production through three quarters, we now expect Gibraltar to produce 115 to 120 million pounds of copper, an increase over our original guidance of 110 to 115 million pounds.”

On October 6, Florence Copper hosted an event in Arizona to mark the onset of commercial production at the world’s first greenfield commercial-scale in-situ copper operation. Representatives of federal, state and local governments attended, including U.S. Environmental Protection Agency (EPA) Administrator Lee Zeldin, along with employees, community and business partners. Administrator Zeldin commented, “After almost two decades without a new copper source anywhere in the U.S., the Florence Copper Mine in Arizona is now open and will produce tens of millions of pounds of copper per year and create hundreds of good-paying jobs to the community. It was great to be there in person yesterday to celebrate the mine’s opening—a huge win for Arizona’s economy and its environment.”

“Bringing Florence Copper into production is a huge accomplishment for our team, and for all of our partners and supporters who made it possible,” Mr. McDonald said. “Florence Copper brings Trekor one step closer to its goal of becoming a leading North American copper producer.”

View video and photo highlights of the event at: Trekor Metals | Trekor Talks

On October 8, Trekor is hosting an analyst and investor site tour at Florence Copper. The presentation, which provides an overview of the in-situ copper operation and an update on the production ramp-up, can be found on Trekor’s website at: Trekor Metals | Corporate Presentations

For further information on Trekor, see the Company’s website at trekormetals.com or contact:

• Investor Enquiries: Brian Bergot, Vice President, Investor Relations – 778-373-4533 or toll-free 1-877-441-4533

Stuart McDonald
President and CEO

No regulatory authority has approved or disapproved of the information contained in this news release

Caution Regarding Forward-Looking Information

This document contains “forward-looking statements” that were based on Trekor’s expectations, estimates and projections as of the dates as of which those statements were made. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “outlook”, “anticipate”, “project”, “target”, “believe”, “estimate”, “expect”, “intend”, “should” and similar expressions.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These included but are not limited to:

• uncertainties about the future market price of copper and the other metals that we produce or may seek to produce;
• changes in general economic conditions, the financial markets and in the market price for our input costs including due to inflationary impacts, such as diesel fuel, acid, steel, concrete, electricity and other forms of energy, mining equipment, and fluctuations in exchange rates, particularly with respect to the value of the U.S. dollar and Canadian dollar, and the continued availability of capital and financing;
• inherent risks associated with mining operations, including our current mining operations at Gibraltar and Florence Copper, and their potential impact on our ability to achieve our production estimates;
• our high level of indebtedness and its potential impact on our financial condition and the requirement to generate cash flow to service our indebtedness and refinance such indebtedness from time to time;
• any increases in interest rates may increase our borrowing costs and impact the profitability of our operations;
• the amounts we are required to pay for our acquisition of Cariboo will increase with higher copper prices;
• the risk of inadequate insurance or inability to obtain insurance to cover our business risks;
• uncertainties related to the accuracy of our estimates of Mineral Reserves (as defined below), Mineral Resources (as defined below), production rates and timing of production, future production and future cash and total costs of production and milling;
• the risk that we may not be able to expand or replace Mineral Reserves as our existing Mineral Reserves are mined;
• the risk that the ramp-up of the Florence Copper commercial production facility does not proceed within projected timelines or cost estimates, or that initial operations do not achieve results consistent with the projections in the Florence Copper Technical Report, including with respect to operating costs, revenue, sustaining capital, rates of return and cash flows from operations;
• our ability to comply with all conditions imposed under the APP and UIC permits for the operation of Florence Copper;
• the availability of, and uncertainties relating to, any additional financing necessary for the continued ramp-up and commercial operation of Florence Copper, including with respect to our ability to obtain any additional financing, if needed, to continue and expand commercial operations at Florence Copper;
• shortages of water supply, critical spare parts, acid, diesel, maintenance service and new equipment and machinery or our ability to manage surplus water on our mine sites may materially and adversely affect our operations and development projects;
• our ability to comply with the extensive governmental regulation to which our business is subject;
• uncertainties related to our ability to obtain necessary title, licenses and permits for our development projects and project delays due to third party opposition;
• uncertainties related to Indigenous people’s claims and rights, and legislation and government policies regarding the same;
• our reliance on the availability of infrastructure necessary for development and on operations, including on rail transportation and port terminals for shipping of our copper concentrate production from Gibraltar, and rail transportation and power for the feasibility of our other British Columbia development projects;
• uncertainties related to unexpected judicial or regulatory proceedings;
• changes in, and the effects of, the laws, regulations and government policies affecting our exploration and development activities and mining operations;
• potential changes to the mineral tenure system in British Columbia, which is undergoing reform including for compliance with the British Columbia Declaration on the Rights of Indigenous Peoples Act (“DRIPA”);
• our dependence solely on our 100% interest in Gibraltar and in due course, Florence Copper for our revenues and our operating cash flows;
• our ability to extend existing concentrate off-take agreements and cathode purchase agreements or enter into new agreements;
• environmental issues and liabilities associated with mining including processing and stockpiling ore;
• labour strikes, work stoppages, or other interruptions to, or difficulties in, the employment of labour in markets in which we operate mines, industrial accidents, equipment failure or other events or occurrences, including third party interference that interrupt the production of minerals in our mines;
• environmental hazards and risks associated with climate change, including the potential for damage to infrastructure and stoppages of operations due to extreme cold, extreme heat, forest fires, flooding, drought, earthquakes or other natural events in the vicinity of our operations;
• litigation risks and the inherent uncertainty of litigation;
• our actual costs of reclamation and mine closure may exceed our current estimates of these liabilities;
• our ability to renegotiate our existing union agreement for Gibraltar when it expires in May 2027;
• the capital intensive nature of our business both to sustain current mining operations and to develop any new projects;
• our ability to develop new mining projects in British Columbia may be impacted by joint decision-making and consent agreements being implemented by the Government of British Columbia with First Nations under DRIPA;
• The ability to develop the New Prosperity Project is subject to the restrictions set out in our June 2025 Tripartite Agreement with the Province of British Columbia and the Tŝilhqot’in Nation (the “Teẑtan Biny Agreement”), under which the New Prosperity Project is subject to a land use planning process with the Province of British Columbia and we are not permitted to be the proponent of any development of the New Prosperity Project;
• our reliance upon key personnel;
• the competitive environment in which we operate;
• the effects of forward selling instruments to protect against fluctuations in copper prices and other input costs including diesel and acid;
• the risk of changes in accounting policies and methods we use to report our financial condition, including uncertainties associated with critical accounting assumptions and estimates;
• uncertainties relating to the war in Ukraine, the escalating military conflict involving Iran and broader Middle East instability, and other future geopolitical events including social unrest, which could disrupt financial markets, commodity markets, supply chains, the price and availability of energy, availability of materials and equipment and execution timelines for any project development;
• uncertainties relating to the delivery of oil through the Strait of Hormuz resulting from Middle East instability, which could have an adverse effect on global economic activity and potentially increase operating costs generally and reduce global demand for copper, and have a material adverse effect on our business, operations, and the feasibility of our development projects;
• changes to U.S. trade policies and tariff measures, including retaliatory tariffs imposed or threatened by Canada and other trading partners, may adversely impact overall economic conditions, copper markets, supply chains, metal prices and input costs; and
• other risks detailed from time-to-time in our annual information forms, annual reports, MD&A, quarterly reports and material change reports filed with and furnished to securities regulators, and those risks which are discussed under the heading “Risk Factors”.

For further information on Trekor, investors should review the Company’s annual report on Form 40-F filed with the United States Securities and Exchange Commission and available at www.sec.gov and home jurisdiction filings that are available at www.sedarplus.ca.

NEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) — Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce that the Company will host an investor presentation on October 21, 2026.

Discussion topics will include HLP003, the Company’s proprietary NSA in Phase 3 development for the adjunctive treatment of major depressive disorder (“MDD”), and HLP004, its proprietary NSA in Phase 2 development for generalized anxiety disorder (“GAD”). The presentation will also include key opinion leaders’ perspectives on the current and evolving depression and anxiety treatment landscape, and a question-and-answer session with members of Helus Pharma’s executive leadership team.

The live webcast will take place on Wednesday, October 21, 2026 at 9:00 a.m. EDT. To access the webcast, please click here or visit the Events & Presentation page of Helus Pharma’s website. The archived webcast will be available on the Company’s website on the Events & Presentations page following the presentation.

About Helus Pharma

Helus Pharma Inc. is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.

Helus Pharma is working to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of MDD that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for GAD. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma™ is a trademark of Helus Pharma Corp.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s plans to host an investor presentation; and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.

Any forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company’s operations; and the risk factors set out in each of the Company’s management’s discussion and analysis for the three months ended June 30, 2026 and the Company’s annual information form for the year ended March 31, 2026, which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

Neither Cboe Canada nor the Nasdaq Global Market stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.
‍
Investor Contact:
Matthew Beck
astr partners
Managing Partner
(917) 415-1750
Matthew.beck@astrpartners.com

Gabriel Fahel
Chief Legal Officer
Helus Pharma
1-866-292-4601
irteam@helus.com – or – media@helus.com

Media Contact:
Victoria Verdeja
RXMD
Public Relations Director
(212) 537-9495
vverdeja@rxmedyn.com

First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumeration

Expands CNSide contracted payer access to approximately 164 million covered lives

HOUSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) — CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has entered into an in-network ancillary provider agreement with Blue Cross and Blue Shield of Florida, Inc. (Florida Blue), effective October 1, 2026.

The agreement establishes contracted reimbursement for the CNSide^® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration test as well as CNSide^® CSF Molecular Profile tests for solid tumors and hematologic malignancies involving the central nervous system. It is the first CNSide payer agreement to include both tumor cell enumeration and molecular profiling.

The Florida Blue agreement adds approximately 6 million covered lives to CNSide’s contracted payer footprint. Combined with previously announced payer agreements, CNSide has now established in-network agreements representing approximately 164 million commercial and Medicare Advantage covered lives, reflecting continued execution of the Company’s national reimbursement strategy.

“This agreement with Florida Blue represents an important milestone in CNSide’s commercial trajectory,” said Marc Hedrick, M.D., Cerenome’s President and Chief Executive Officer. “By expanding contracted reimbursement to both cellular and molecular CSF testing, we are advancing CNSide as a broader CSF diagnostics platform for CNS oncology, combining tumor-cell analysis and molecular profiling to better characterize and monitor cancers involving the central nervous system.”

The Florida Blue agreement expands the scope of CNSide’s contracted reimbursement beyond tumor cell detection in leptomeningeal metastases to include molecular profiling of CNS malignancies. CNSide^® CSF Molecular Profile – Solid Tumor provides DNA and RNA molecular profiling of CSF for patients with suspected or confirmed primary CNS tumors or solid tumors metastatic to the CNS, including brain and leptomeningeal metastases. CNSide^® CSF Molecular Profile – Hematologic Malignancy provides DNA and RNA molecular profiling of CSF for patients with suspected or confirmed hematologic malignancies involving the CNS. CNSide^® CSF Molecular Profile tests are now commercially available through CNSide.

The DNA and RNA CSF molecular profiling approach underlying CNSide^® CSF Molecular Profile was recently evaluated in a peer-reviewed, real-world study of 1,391 evaluable CSF specimens from patients being evaluated for primary CNS tumors, metastatic CNS disease, and hematologic malignancies involving the CNS, published in The Journal of Liquid Biopsy.

The clinical utility of CNSide CSF tumor cell analysis in leptomeningeal metastases is supported by evaluation in 12 peer-reviewed publications, prospective multicenter evidence from the FORESEE clinical study, and real-world clinical experience. Since 2020, more than 11,000 CNSide^® tests have been performed at more than 120 U.S. cancer institutions, supporting clinical decision-making across academic and community oncology practices nationwide. 

About Florida Blue
Driven by its mission of helping people and communities achieve better health, Florida Blue is the leading health insurer in Florida, and part of GuideWell, a not-for-profit health solutions company.  Florida Blue offers a range of health plans and personalized care programs for individuals, families, businesses of all sizes, and Medicare beneficiaries. For over 80 years, the organization has been member centric and committed to making health care as accessible and affordable as possible. Serving more than six million members across all 67 Florida counties, Florida Blue has more than 7,000 employees, is headquartered in Jacksonville, Fla., is owned by its policyholders, and is an independent licensee of the Blue Cross Blue Shield Association.

About CNSide Diagnostics, LLC 
CNSide Diagnostics, LLC is a wholly owned subsidiary of Cerenome, Inc. that develops and commercializes cerebrospinal fluid (CSF)-based diagnostic tests for cancers involving the central nervous system. The CNSide^® CSF diagnostics platform combines cellular analysis, biomarker characterization, and molecular profiling to support the detection, characterization, and longitudinal assessment of CNS malignancies. CNSide currently offers CNSide^® CSF Tumor Cell Enumeration for patients with suspected or confirmed leptomeningeal metastases and plans to launch CNSide^® CSF Molecular Profile tests for molecular characterization of primary CNS tumors, solid tumors metastatic to the CNS, and hematologic malignancies involving the CNS in October 2026. For more information, visit https://www.cnside-dx.com

About Cerenome
Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The CNSide^® CSF diagnostics platform combines cellular and molecular testing to support the detection, characterization, and longitudinal assessment of cancers involving the CNS. Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation. By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value. For more information, visit https://www.cerenome.com. 

Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.

Investor Contact
CORE IR
IR@cerenome.com

TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 third quarter earnings conference call on Thursday, November 5, 2026, at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks.

To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on the Company’s website.

About Cronos Group Inc.
Cronos is a global cannabis company focused on scaling leading consumer goods products through research and development and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS®, LIT™ and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com.

Forward-looking Statements 
This press release may contain information that may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, “Forward-looking Statements”). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “plan”, “anticipate”, “intend”, “potential”, “estimate”, “believe” or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about the Company’s intention to build an international iconic brand portfolio by scaling leading consumer goods products through R&D and innovation. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks. Financial results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026, each of which has been filed on SEDAR+ and EDGAR and can be accessed at www.sedarplus.ca and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.

For further information, please contact: 

Investor Relations Contact:
Harrison Aaron 
Investor Relations 
Tel: (416) 504-0004 
investor.relations@thecronosgroup.com

WASHINGTON, Oct. 08, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that it will release financial results for the third quarter ended September 30, 2026, before the New York market opens on Thursday, October 29, 2026.

A conference call will be held to discuss these financial results on Thursday, October 29, 2026, at 9:00 a.m. Eastern Time and will be hosted by senior management.

The conference call will be simulcast live on the Internet and can be accessed by logging onto the Company’s investor relations website. A replay of the webcast will be available on the Company’s investor relations website for 90 days.

About FTI Consulting
FTI Consulting, Inc. is a leading global expert firm for organizations facing crisis and transformation, with more than 8,100 employees located in 32 countries and territories as of June 30, 2026. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalized and independently managed. The Company generated $3.8 billion in revenues during fiscal year 2025. More information can be found at www.fticonsulting.com.

FTI Consulting, Inc. 
555 12^th Street NW
Washington, DC 20004
+1.202.312.9100

Investor Contact:
Mollie Hawkes
+1.617.747.1791        
mollie.hawkes@fticonsulting.com

Revenue grew 59% year-over-year to $16.2 million; GCC revenue more than doubled (+107%)

Gross profit grew 35% year-over-year to $2.9 million

Operating margin improved to (3.5%) from (4.1%) as operating expenses fell to 25% of revenue from 29%

Recurring revenue rose to 88% of total revenue; dollar-pegged revenue reached 44% of revenue (+107%)

Net Dollar Retention of 123%

Q2 2026 revenue of $7.99 million, up 51% year-over-year

Subsequent to period end, $14.5 million gross private placement signed in August 2026

DUBAI, United Arab Emirates, Oct. 08, 2026 (GLOBE NEWSWIRE) — Swvl Holdings Corp (“Swvl” or the “Company”, and together with the Company’s subsidiaries, the “Group”) (NASDAQ: SWVL), a leading provider of technology-enabled mass mobility solutions for enterprises and governments, today announced its financial results for the six months ended June 30, 2026 (“H1 2026”).

Swvl sustained its growth trajectory through the first half of the year, growing H1 2026 revenue by 59% to $16.2 million compared to $10.2 million for the six months ended June 30, 2025 (“H1 2025”). Growth was led by the Gulf Cooperation Council (“GCC”), where revenue increased by 107% in H1 2026 over H1 2025, and continued expansion in Egypt. The Group’s revenue base continues to shift increasingly towards being recurring and dollar-pegged.

Operating leverage continued to build. While operating expenses increased in H1 2026 from H1 2025, operating expenses declined to 25% of revenue in H1 2026 from 29% in H1 2025, and the operating margin improved to (3.5%) in H1 2026 from (4.1%) in H1 2025, even as the Company absorbed start-up costs in new markets, and higher sales and marketing investment. Consolidated net dollar retention of 123% reflected continued expansion within the Company’s existing customer base.

H1 2026 Financial Highlights

• Revenue: $16.2 million, up 59% year-over-year from $10.2 million
• Gross profit: $2.9 million, up 35% year-over-year from $2.2 million; gross margin of 18.2% in H1 2026 (vs 21.5% in H1 2025), reflecting a higher UAE revenue mix
• Operating loss of $0.57 million in H1 2026 vs $0.42 million in H1 2025; operating margin improved to (3.5%) from (4.1%)
• GCC revenue: $7.1 million in H1 2026, up 107% year-over-year from $3.4 million in H1 2025
• Egypt revenue: $9.1 million in H1 2026, up 35% year-over-year from $6.8 million in H1 2025
• Recurring revenue: $14.2 million in H1 2026, up 64% year-over-year from $8.68 million in H1 2025; 88% of total revenue (vs 85% in H1 2025)
• Dollar-pegged revenue: $7.1 million in H1 2026, up 107% year-over-year from $3.4 million in H1 2025; 44% of total revenue (vs 34% in H1 2025)
• Consolidated Net Dollar Retention: 123%
• Operating expenses (general and administrative (G&A) and sales and marketing (S&M)): $4.1 million in H1 2026, equal to 25% of revenue in H1 2026, down from 29% of revenue in H1 2025

Revenue Performance

Revenue increased 59% to $16.2 million in H1 2026 from $10.2 million in H1 2025, with growth contributed by both of the Company’s core markets. The GCC was the primary driver, more than doubling year-over-year, while Egypt grew 35%. In addition, second-quarter 2026 revenue was $8.0 million as compared to $5.28 million in the second quarter 2025, up 51% year-over-year.

Recurring revenue grew 64% from $8.68 million in H1 2025 to $14.2 million in H1 2026, and represented 88% of total revenue, in comparison to 85% in H1 2025. Transactional revenue was $2.0 million, or 12% of total revenue in H1 2026, in comparison to $1.5 million, or 15% of total revenue in H1 2025. The Company’s enterprise-first strategy continues to drive longer-duration contracts, higher average revenue per account, and more predictable revenue streams.

Revenue Quality Metrics

Recurring Revenue: recurring revenue represented 88% of total revenue in H1 2026, in comparison to 85% in H1 2025. Long-term enterprise contracts continued to provide predictable cash flows and reduce the impact of seasonality.

Dollar-Pegged Revenue: dollar-pegged revenue grew 107% to $7.1 million and represented 44% of total revenue, in comparison to 34% in H1 2025. Continued expansion in the GCC and the launch of the United States and United Kingdom are expected to continue shifting the revenue base toward hard-currency earnings and reducing foreign currency exchange exposure.

Net Dollar Retention (“NDR”): consolidated NDR was 123%, indicating that existing customers expanded their spend with Swvl year-over-year. We view this metric as reflecting strong product-market fit and the Company’s ability to grow within its installed customer base without incremental acquisition costs.

Operating Expense Discipline

Operating Expenses (G&A and S&M combined) were $4.1 million in H1 2026, compared to $2.9 million in H1 2025, an increase of 39% against revenue growth of 59%. As a percentage of revenue, operating expenses decreased from 29% to 25%, underscoring the operating leverage in Swvl’s business model as it scales.

General and Administrative Expenses increased by 29% to $3.7 million, compared to $2.9 million in H1 2025, however, G&A has decreased as a percentage of revenue from 28.6% in H1 2025, to 25% in H1 2026. The increase in expense is driven primarily by staff costs of $2.5 million in H1 2026 as compared to $1.5 million in H1 2025, as the Company started to build out teams for its expansion and product plans. This was partly offset by a 59% reduction in professional fees from $0.66 million in H1 2025 to $0.27 million in H1 2026.

Selling and Marketing Expenses were $0.31 million in H1 2026, compared to $0.01 million in H1 2025, as the Company invested in its commercial team to support GCC and new-market expansion.

Balance Sheet and Liquidity

Cash and cash equivalents were $2.1 million at June 30, 2026, compared to $4.4 million at December 31, 2025. Net cash used in operating activities was $2.0 million, driven principally by a $1.9 million increase in trade and other receivables as revenue scaled, with the UAE accounting for the majority of the increase.

Subsequent to period end, on August 25 and 26, 2026, the Company entered into securities purchase agreements for the issuance and sale of an aggregate of 10,017,714 Class A Ordinary Shares in private placement transactions for aggregate gross proceeds of approximately $14.5 million, materially strengthening the Company’s liquidity position.

Mostafa Kandil, Chief Executive Officer of Swvl, commented:

“H1 2026 delivered 59% revenue growth, with the GCC revenue more than doubling and our revenue base now 88% recurring and 44% dollar-pegged. With the $14.5 million private placements signed in August 2026, we believe that we have the capital to scale across the GCC, the United Kingdom and the United States while continuing to drive toward sustained operating profitability.”

Ahmed Misbah, Chief Financial Officer of Swvl, added:

“Revenue grew 59% while operating expenses grew 39%, taking operating expenses down to 25% of revenue from 29% and improving operating margin despite absorbing new-market and ramp-up costs. Net dollar retention of 123% and recurring revenue of 88% give us a predictable base to build on.”

Financial Summary:

For H1 2026, Swvl reported revenue of $16.2 million (up 59% from $10.2 million in H1 2025), gross profit of $2.9 million (up 35%), and an operating loss of $0.6 million (vs $0.4 million). Operating expenses were $4.1 million, equal to 25% of revenue, down from 29%. GCC revenue grew 107% to $7.1 million, while Egypt revenue grew 35% to $9.1 million. Recurring revenue represented 88% of total revenue and dollar-pegged revenue represented 44%. Consolidated net dollar retention was 123%. The Company announced $14.5 million in gross proceeds from private placement transactions executed in August 2026.

Forward-Looking Statements:

This press release contains “forward-looking statements” relating to future events. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters.

These forward-looking statements include, but are not limited to, statements regarding future events and other statements that are not historical facts. For example, Swvl is using forward-looking statements when it discusses that the Group’s revenue base continues to shift increasingly towards being recurring and dollar-pegged, that it views the NDR metric as reflecting strong product-market fit and its ability to grow within its installed customer base without incremental acquisition costs, that its operating expenses as a percentage of revenue underscores the operating leverage in its business model as it scales, its belief that it has the capital to scale across the GCC, the United Kingdom and the United States while continuing to drive toward sustained operating profitability. These statements are based on the current expectations of Swvl’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability.

Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Swvl. These statements are subject to a number of risks and uncertainties regarding Swvl’s business, and actual results may differ materially. In particular, the financial results presented herein are unaudited interim results and remain subject to year-end audit adjustments.

In addition, forward-looking statements provide Swvl’s expectations, plans, or forecasts of future events and views as of the date of this communication. Swvl anticipates that subsequent events and developments could cause Swvl’s assessments and projections to change. However, while Swvl may elect to update these forward-looking statements in the future, Swvl specifically disclaims any obligation to do so.

These forward-looking statements should not be relied upon as representing Swvl’s assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon any forward-looking statements. Except as otherwise required by law, Swvl undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC’s website, www.sec.gov, and in subsequent SEC filings.

About Swvl

Swvl Holdings Corp (NASDAQ: SWVL) is a leading provider of technology-driven mobility solutions for enterprises and governments. Its platform leverages real-time data, adaptive networks, and advanced technology to deliver safer, more reliable, and sustainable transportation solutions. Swvl serves corporate clients, government institutions, schools, and healthcare providers across Egypt, the Kingdom of Saudi Arabia, the UAE, Kuwait, Qatar, the United Kingdom, and the United States. For more information, visit www.swvl.com.

Contact:

Investor relations: ir@swvl.com

Ahmed Misbah, CFO of Swvl: ahmed.misbah@swvl.com

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Man Group PLC
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Sthree plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	07/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	NO

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	1p ordinary
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:	6,699,267	5.50
(2)   Cash-settled derivatives:	3,927,942	3.22	15,497	0.01
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	10,627,209	8.73	15,497	0.01

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
1p ordinary	Equity swap	Increasing a short position	900	3.0000 GBP

        
(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii)        Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	08/10/2026
Contact name:	Graham Keene
Telephone number:	+44 20 7144 2259

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

• Wide, strong gold and copper intersected in all four infill holes drilled at the eastern end of the Western Zone
• Important interval intersected in K-26-268 supporting potential improvements to modelled mineralization
• Primary porphyry mineralization intersected at depth in multiple holes, providing a new exploration target for potential resource expansion

TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) — NorthWest Copper Corp. (“NorthWest” or the “Company”) (TSX-V: NWST) is pleased to report additional drill results from its 2026 exploration program at the Company’s 100% owned Kwanika project in British Columbia. The four holes reported from the approximately 12,000 metre, 40-hole, program were drilled at the eastern end of the Western Zone and were designed to improve confidence in the mineral resource and extend mineralization.

The results demonstrate strong gold-copper mineralization at the eastern end of the Western Zone, highlighted by hole K-26-263, which intersected 108.7 metres grading 0.70% copper and 1.69 g/t gold (2.53% copper equivalent (“CuEq”)) and hole K-26-276 which intersected 51.5 metres grading 1.15% copper and 1.47 g/t gold (2.77% CuEq). The four holes confirm continuity of mineralization along the section and continue to demonstrate a relatively high gold-to-copper ratio.

Holes K-26-268 and hole K-26-263 also intersected short intervals of primary copper-gold porphyry mineralization beneath the known structurally controlled mineralized zones, providing an additional opportunity for follow-up exploration and potential resource expansion. Notably, hole K-26-263 returned 18 metres of 0.32% Cu and 0.53g/t Au (0.91% CuEq) at the bottom of the hole starting at 467 metres.

Western Zone Drill Hole Highlights:

K-26-263: 108.7 metres of 0.70% Cu and 1.69 g/t Au (2.53% CuEq) from 352.8 metres

K-26-267: 26.6 metres of 0.27% Cu and 1.70 g/t Au (2.11% CuEq) from 476.0 metres        

K-26-268: 58.6 metres of 0.61% Cu and 0.92 g/t Au (1.61% CuEq) from 343.0 metres        

K-26-276: 51.5 metres of 1.15% Cu and 1.47 g/t Au (2.77% CuEq) from 312.5 metres

Paul Olmsted, CEO of NorthWest stated: “These results help confirm the strength of the Western Zone, with long intervals of strong gold-copper mineralization, excellent continuity and grades that increase our confidence in the known mineralized system. We are particularly encouraged by hole K-26-268, as the intersection was better than expected. With approximately 32 additional holes planned for release from the 2026 drill program, we are seeing encouraging progress toward our objectives of upgrading confidence in the existing resource, extending known mineralization and identifying opportunities for further growth.”

2026 Kwanika Exploration Program

The 2026 exploration program is in progress and on track to deliver approximately 40 drill holes totalling approximately 12,000 metres at the Kwanika Central deposit this year, with collar locations shown in Figure 1.

Figure 1: Kwanika Central 2026 drill hole location map

The 2026 drill program is designed to upgrade and expand mineral resources in the Pit Zone, North Pit Extension Zone and Western Zone to support an updated mineral resource estimate at Kwanika. A drill hole spacing of 50 metres is being targeted to support classification of mineral resources in the Indicated category.

Geoff Chinn, VP Business Development and Exploration added: “These four new holes represent high angle drill intercepts in the Western Zone with more representative grades and widths at approximately 50 metre spacing that are expected to support upgrading mineral resources to the Indicated category. Results are consistent with the existing geological model, validating our current interpretation. The drilling also continues to demonstrate the continuity of the palladium enriched mineralized horizon, which provides both a potential credit and an important marker for geological correlation. Importantly, holes K-26-263 and K-26-268 both intersected short deeper unfractured primary copper-gold porphyry mineralization (Unit 16) beneath the Western Zone mineralization providing an additional target for follow-up exploration.”

Kwanika Exploration Drill Hole Summaries

Results for four new drill holes are presented on cross-section 351400 E (Figure 2) with composited mineralized intersections listed in Table 1 and collar locations provided in Table 2. The cross-section is located at the eastern end of the Western Zone. The holes were designed to improve confidence in the mineralization by reducing drill hole spacing to approximately 50 metres and test up-dip and down-dip extensions.

Figure 2: Cross-Section 351400 E showing 2026 drill results

Western Zone:

Hole K-26-263 was drilled with HQ to 315 metres, then NQ core, and sampled on 2-metre intervals from half sawn core and drilled on 170° azimuth at a -83° dip to a depth of 495 metres.

After 27 metres of overburden the hole intersected post-mineral Cretaceous sediments to 305 metres then maroon (oxidized) mineralized monzonite to 353 metres (Comp 1) correlated to Unit 15. Beige mineralized potassic altered fractured healed monzonite characteristic of higher grades at Kwanika continues to 465 metres (Comp 2, 3, 4, 5). Mineralized intervals were separated by late dykes. Composites 2 and 3 were correlated to Unit 1, whereas composites 4 and 5 were correlated to Unit 2 due to their higher palladium content. Beyond this, less fractured mineralized orange monzonite porphyry with regular vein stockwork was intersected between 467 and 485 metres (Comp 6).

Hole K-26-267 was drilled with HQ to 300 metres, then NQ core, and sampled on 2-metre intervals from half sawn core and drilled on 0° azimuth at a -90° dip to a depth of 602 metres.

After 22 metres of overburden the hole intersected post-mineral Cretaceous sediments to 266 metres then intersected an unmineralized maroon diorite to 308 metres. A sequence of unmineralized potassic altered orange monzodiorite porphyry and crosscutting post-mineralization pale green dykes was encountered to 372 metres followed by a grey strongly propylitic altered diorite to 425 metres hosting elevated copper values. A thick sequence of dominantly potassic altered monzodiorite continued to 602 metres, variably overprinted by sericite-chlorite alteration and mineralized intervals associated with quartz stockwork veining, including composites 9, 10 ,11 correlated to Unit 1 and composite 12 assigned to Unit 2 due to its relatively high palladium content.

Hole K-26-268 was drilled with HQ to 228 metres then NQ core and sampled on 2-metre intervals from half sawn core and drilled on 0° azimuth at a -90° dip to a depth of 552 metres.

After 27 metres of overburden the hole intersected post mineral Cretaceous sediments to 302 metres then intersected an unmineralized green diorite to 340 metres followed by a sequence of beige to pink potassic altered monzonite that is crosscut by light green to maroon post mineralization dykes to 505 metres where mineralization in the monzonite is associated with silicification, irregular veining, and stockwork. Composite 13 was correlated to Unit 1 and composite 14 to Unit 2 due to its palladium enrichment. Composite 15 was hosted in a light green chlorite altered porphyritic dyke, whereas composite 16 seems to be a new fractured healed mineralized monzonite unit and composite 17 is hosted in a competent grey green propylitic altered monzodiorite with spaced quartz stringers at the end of the hole.

Hole K-26-276 was drilled with HQ to 228 metres then NQ core and sampled on 2-metre intervals from half sawn core and drilled on 170° azimuth at a -77° dip to a depth of 430 metres.

After 30 metres of overburden the hole intersected post mineral Cretaceous sediments to 309 metres then intersected a mineralized maroon-dark green monzonite supergene interval (Comp 19) to 364 metres. A late dyke continued to 375 metres followed by a sequence of mineralized beige potassic altered monzonite to 430 metres (Comps 20, 21) crosscut by a late dyke between 406 and 408 metres. Composites 20 and 21 were correlated to mineralization Unit 2 due to high palladium content, and suggesting Unit 1 is incorporated into the supergene zone above it.

Hole Summary, overall, infill drilling on Section 351400 E upgraded the geological correlation and grade continuity of the Western Zone. Hole K-26-268 returned a better than expected interval, whereas K-26-267 shows mineralization thinning towards the north. Palladium in Unit 1, a potential metal credit, demonstrates excellent continuity and provides a key marker horizon for correlating units relative to it. While short, confirmation of porphyry mineralization beneath the fracture-healed hosted mineralized zones at the end of two holes provide a new exploration opportunity for follow-up.

Table 1: Drill Results in this News Release1 2
Comp	Hole	From	To	Length	Area	Cu	Au	Ag	Pd	CuEq	True Width	Mineralized
#		(m)	(m)	(m)		(%)	(g/t)	(g/t)	(g/t)	(%)	Est. (m)	Unit
1	K-26-263	327.0	349.0	22.0	West	0.34	0.33	1.33	0.01	0.71	14.7	Supergene Cu 15
2	K-26-263	352.8	461.6	108.7	West	0.70	1.69	1.90	0.14	2.53	72.7
3	Including	352.8	413.7	60.9	West	0.87	2.39	2.18	0.04	3.46	40.7	Higher-Grade Au 1
4	And	416.9	441.4	24.5	West	0.42	0.87	1.24	0.23	1.37	16.4	Higher-Grade Au 2
5	And	448.3	461.6	13.2	West	0.91	1.12	3.08	0.59	2.15	8.8	Higher-Grade Au 2
6	K-26-263	467.0	485.0	18.0	West	0.32	0.53	1.77	0.01	0.91	12.0	Porphyry Au-Cu 16
7	K-26-267	423.1	431.2	8.1	West	0.26	0.61	2.62	0.01	0.95	4.6	None defined
8	K-26-267	459.4	468.5	9.1	West	0.43	0.27	2.13	0.00	0.75	5.2	Higher-Grade Au 1
9	K-26-267	476.0	502.6	26.6	West	0.27	1.70	1.97	0.02	2.11	15.2	Higher-Grade Au 1
10	Including	476.0	477.7	1.7	West	0.54	15.40	4.20	0.00	17.08	1.0	Higher-Grade Au 1
11	And	477.7	488.4	10.6	West	0.40	1.13	2.81	0.01	1.65	6.1	Higher-Grade Au 1
12	K-26-267	576.8	590.6	13.7	West	0.41	0.71	3.26	0.12	1.22	7.9	Higher-Grade Au 2
13	K-26-268	343.0	401.6	58.6	West	0.61	0.92	1.51	0.02	1.61	33.6	Higher-Grade Au 1
14	K-26-268	422.4	453.7	31.3	West	0.49	1.64	1.25	0.09	2.26	18.0	Higher-Grade Au 2
15	K-26-268	464.0	482.0	18.0	West	0.68	0.81	1.57	0.02	1.57	10.3	None defined
16	K-26-268	489.7	527.0	37.3	West	0.31	0.39	0.77	0.02	0.74	21.4	None defined
17	K-26-268	537.0	547.0	10.0	West	0.50	0.25	0.61	0.00	0.78	5.7	Porphyry Au-Cu 16
18	K-26-276	312.5	364.0	51.5	West	1.15	1.47	3.66	0.07	2.77	38.3
19	K-26-276	312.5	343.7	31.2	West	0.94	0.81	3.36	0.01	1.86	23.2	Supergene Cu 15
20	K-26-276	343.7	364.0	20.3	West	1.47	2.48	4.12	0.16	4.18	15.1	Higher-Grade Au 2
21	K-26-276	381.0	428.0	47.0	West	1.10	1.06	3.27	0.26	2.28	34.9	Higher-Grade Au 2

Table 2: Drill Collar Information3
Hole	Collar X	Collar Y	Collar Z	Collar Azimuth	Collar Dip	Final Length	Core Size
K-26-263	351400	6156206	1001	170	-83	495	HQ, NQ
K-26-267	351401	6156251	1003	0	-90	602	HQ, NQ
K-26-268	351400	6156206	1001	0	-90	552	HQ, NQ
K-26-276	351400	6156206	1001	170	-77	430	HQ, NQ

Quality Assurance / Quality Control

Drilling at Kwanika in 2026 was designed and supervised by NorthWest and implemented by InData Geoscience with assay QA/QC checks by Explore Geosolutions. Samples were collected, tracked and an external QA/QC program was implemented using coarse blanks and certified prepared blanks and standards to monitor analytical accuracy and precision. The samples were sealed on site and shipped to Activation Laboratories Ltd. (“Actlabs”) in Kamloops, BC. The laboratory’s internal quality control system complies with global certifications for quality ISO 17025. Drill core samples were analyzed using a combination of Actlabs multi-element 1F2 analysis for low level concentrations (4-Acid Digestion, ICP-OES) and the 8-4 Acid ICP-OES analysis for higher level concentrations (4-Acid Digestion, ICP-OES with automatic over limits for base metals and silver). Gold, platinum and palladium assaying was completed with 1C-OES method, using a 30-gram fire assay with ICP finish analysis. In addition, about 5% of the sample pulps are re-assayed at a secondary laboratory to confirm reproducibility and check for bias.

Technical aspects of this news release have been reviewed, verified, and approved by Geoff Chinn, P.Geo., VP Business Development and Exploration for NorthWest, who is a qualified person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

About NorthWest:

NorthWest is a copper-gold exploration and development company with a pipeline of advanced and early-stage projects in British Columbia, including Kwanika-Stardust, Lorraine-Top Cat and East Niv. With a robust portfolio in an established mining jurisdiction, NorthWest is well positioned to participate fully in strengthening global copper and gold markets. The Company is committed to responsible mineral exploration, working collaboratively with First Nations to help ensure future development incorporates stewardship best practices and respects traditional land use. Additional information can be found on the Company’s website at www.northwestcopper.ca.

On Behalf of NorthWest
“Paul Olmsted”
CEO, NorthWest Copper

For further information, please contact: 
416-457-3333
info@northwestcopper.ca  

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Information 

 This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussion with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often, but not always using phrases such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to statements with respect to; plans and intentions of the Company; proposed exploration and development of NorthWest’s exploration property interests; the Company’s ability to finance future operations; mine plans; magnitude or quality of mineral deposits; the development, operational and economic results of current and future potential economic studies; adding the Lorraine resource to the Kwanika-Stardust Project; the Company’s current goals; geological interpretations; the estimation of Mineral Resources; anticipated advancement of mineral properties or programs; future exploration prospects; the completion and timing of technical reports; future growth potential of NorthWest; and future development plans.

All statements, other than statements of historical fact, included herein, constitutes forward-looking information. Although NorthWest believes that the expectations reflected in such forward-looking information and/or information are reasonable, undue reliance should not be placed on forward-looking information since NorthWest can give no assurance that such expectations will prove to be correct. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information, including the risks, uncertainties and other factors identified in NorthWest’s periodic filings with Canadian securities regulators. Forward-looking information are subject to business and economic risks and uncertainties and other factors that could cause actual results of operations to differ materially from those contained in the forward-looking information. Important factors that could cause actual results to differ materially from NorthWest’s expectations include risks associated with the business of NorthWest; risks related to reliance on technical information provided by NorthWest; risks related to exploration and potential development of the Company’s mineral properties; business and economic conditions in the mining industry generally; fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of drill results and the geology, continuity and grade of mineral deposits; the need for cooperation of government agencies and First Nation groups in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; and other risk factors as detailed from time to time and additional risks identified in NorthWest’s filings with Canadian securities regulators on SEDAR+ in Canada (available at www.sedarplus.com). 

Forward-looking information is based on estimates and opinions of management at the date the information is made. NorthWest does not undertake any obligation to update forward-looking information except as required by applicable securities laws. Investors should not place undue reliance on forward-looking information.

^{1 Estimated true widths based on collar azimuth and dip and the average dip of the mineralized zone
2 CuEq assumes metal prices of $3,100/oz gold, $4.50/lb copper, $36/oz silver and $1,100/oz palladium metal recoveries of 96% gold, 90% copper, 96% silver, 0% palladium and calculated as follows: Cu +100* ( (Au /31.1035 * Au Price * Au Rec) / (Cu Price * 2204.62 * Cu Rec) + (Ag /31.1035 * Ag Price * Ag Rec) / (Cu Price*2204.62 * Cu Rec) + (Pd /31.1035 * Pd Price * Pd Rec) / (Cu Price*2204.62 * Cu Rec))
3 Collar coordinates reference UTM Zone 10N NAD83.}

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/76f09ce2-007f-4f4f-a1d5-4b2cd5329dd8

https://www.globenewswire.com/NewsRoom/AttachmentNg/e91ee839-68a0-4ccc-b184-6614f75dd0d9

Transaction high-grades Devon’s portfolio, monetizes at an attractive valuation and enhances financial flexibility

HOUSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) — Devon Energy Corp. (NYSE: DVN) today announced it has entered into a definitive agreement to sell its Eagle Ford assets to Crescent Energy Company for total consideration of $4.2 billion in cash, subject to customary closing adjustments.

“This sale is a direct outcome of our ongoing portfolio review, and it sharpens our focus on the highest-return, longest-duration assets,” said Clay Gaspar, President and Chief Executive Officer. “Over the past several years, we have leveraged technology to lower costs and increase productivity while coring up our Eagle Ford acreage footprint, and the attractive price agreed to reflects both the quality of the assets and that work. Selling a relatively mature asset into a strong commodity price environment improves our go-forward capital efficiency and allows us to accelerate share buybacks, strengthen our balance sheet and increase long-term value for shareholders.”

TRANSACTION HIGHLIGHTS

• Asset details: The Eagle Ford assets to be sold consist of approximately 90,000 net acres in Karnes, DeWitt, and Gonzales Counties, Texas. The assets represent approximately 4% of Devon’s total BOE production.
• Attractive valuation: The $4.2 billion purchase price fully reflects the value of Devon’s Eagle Ford production and inventory and is accretive on a per share basis to Free Cash Flow and Net Asset Value.
• Portfolio high-grading and improved capital efficiency: The divestiture lengthens Devon’s inventory life, lowers the go-forward corporate breakeven and reduces the corporate base production decline rate.
• Financial flexibility: After-tax proceeds will be used to accelerate share repurchases and to strengthen the balance sheet through debt reduction.

“This transaction is our strategy at work,” added Gaspar. “We acted decisively and countercyclically while navigating a volatile macro environment and received a price above our internal hold case, including potential strategic upside. This divestiture builds on the accretive steps taken in 2026 – combining with Coterra, adding premier Delaware Basin inventory in the federal lease sale and investing in the Solitude pipeline to integrate our gas production from wellhead to market. This marks meaningful progress in our disciplined portfolio review. We remain focused on improving the quality and longevity of our portfolio, expanding our margins and enhancing long-term value per share.”

TIMING AND ADVISORS

The transaction has an effective date of July 1, 2026 and is expected to close around year-end 2026, subject to regulatory approvals and customary closing conditions. Devon will provide additional details, including the impact on its outlook, with its third-quarter 2026 results on November 5, 2026 and conference call and webcast on November 6, 2026.

RBC Richardson Barr is serving as exclusive financial advisor and Kirkland & Ellis LLP is serving as legal advisor to Devon.  

ABOUT DEVON ENERGY

Devon Energy is a leading oil and gas producer in the U.S. with a diversified multi-basin portfolio headlined by a world-class acreage position in the Delaware Basin. Devon’s disciplined cash-return business model is designed to achieve strong returns, generate free cash flow and return capital to shareholders, while focusing on safe and sustainable operations. For more information, please visit www.devonenergy.com.

Investor Contact investor.relations@dvn.com 281-589-5705

Media Contact devonmediarelations@dvn.com 405-552-7560

FORWARD-LOOKING STATEMENTS

This press release includes “forward-looking statements” within the meaning of the federal securities laws. Such statements include those concerning strategic plans, our expectations and objectives for future operations, as well as other future events or conditions, and are often identified by use of the words and phrases “expects,” “believes,” “will,” “would,” “could,” “continue,” “may,” “aims,” “likely to be,” “intends,” “forecasts,” “projections,” “estimates,” “plans,” “expectations,” “targets,” “opportunities,” “potential,” “anticipates,” “outlook” and other similar terminology. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that Devon expects, believes or anticipates will or may occur in the future are forward-looking statements. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond our control. Consequently, actual future results could differ materially and adversely from our expectations due to a number of factors, including, but not limited to: the delay or failure to consummate the transaction due to unsatisfied closing conditions or otherwise; the actual amount of proceeds received due to purchase price adjustments, and the ultimate use of those proceeds; changes in commodity prices, market conditions or other circumstances that could negatively impact Devon’s ability to complete the anticipated share repurchases and debt reductions; and any of the other risks and uncertainties discussed in Devon’s 2025 Annual Report on Form 10-K (the “2025 Form 10-K”) or other filings with the Securities and Exchange Commission (“SEC”).

The forward-looking statements included in this press release speak only as of the date of this press release, represent management’s current reasonable expectations as of the date of this press release and are subject to the risks and uncertainties identified above as well as those described elsewhere in the 2025 Form 10-K and in other documents we file from time to time with the SEC. We cannot guarantee the accuracy of our forward-looking statements, and readers are urged to carefully review and consider the various disclosures made in the 2025 Form 10-K and in other documents we file from time to time with the SEC. All subsequent written and oral forward-looking statements attributable to Devon, or persons acting on its behalf, are expressly qualified in their entirety by the cautionary statements above. We do not undertake, and expressly disclaim, any duty to update or revise our forward-looking statements based on new information, future events or otherwise.